DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform
by Zacks Equity Research
IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Veeva Systems (VEEV) Offerings Adopted by SK Life Science
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.
Best Growth Stocks to Buy for January 15th
by Zacks Equity Research
DVA, AZZ and ELF made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 15, 2024.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Beat the Market the Zacks Way: DaVita, Block, Home Depot in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics
by Zacks Equity Research
Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.
Don't Overlook These Top Value Stocks in January It's Time to Buy
by Shaun Pruitt
With "A" Zacks Style Scores grades for Value here are three top-rated stocks with fundamental valuations that shouldn't be overlooked at the moment.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.
LabCorp (LH) to Expand Clinical Trails Access With New Pact
by Zacks Equity Research
LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
by Zacks Equity Research
DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
Medtronic's (MDT) Percept RC DBS System Secures FDA Approval
by Zacks Equity Research
Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.
Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.
Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.